Barclays Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price

Oruka Therapeutics (NASDAQ:ORKA) had its price objective boosted by equities researchers at Barclays from $48.00 to $50.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 25.41% from the company’s previous close.

A number of other research analysts have also recently commented on ORKA. Stifel Nicolaus boosted their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday. Piper Sandler initiated coverage on shares of Oruka Therapeutics in a research report on Thursday, December 18th. They set an “overweight” rating and a $75.00 target price on the stock. UBS Group initiated coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.67.

Oruka Therapeutics Stock Performance

Shares of ORKA stock traded up $7.88 during mid-day trading on Friday, hitting $39.87. The company’s stock had a trading volume of 1,460,790 shares, compared to its average volume of 440,491. Oruka Therapeutics has a 52-week low of $5.49 and a 52-week high of $41.19. The business has a 50-day moving average price of $32.68 and a 200 day moving average price of $27.32. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -20.98 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.16. Equities research analysts predict that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the transaction, the insider owned 34,018 shares in the company, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 21,000 shares of company stock worth $663,530. 24.69% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ORKA. Caitong International Asset Management Co. Ltd purchased a new position in shares of Oruka Therapeutics during the 4th quarter worth $67,000. Seven Fleet Capital Management LP purchased a new position in Oruka Therapeutics during the fourth quarter worth about $159,000. Invesco Ltd. increased its position in shares of Oruka Therapeutics by 777.1% during the fourth quarter. Invesco Ltd. now owns 143,121 shares of the company’s stock valued at $4,338,000 after acquiring an additional 126,803 shares during the last quarter. Virtus Investment Advisers LLC purchased a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $267,000. Finally, RTW Investments LP lifted its holdings in shares of Oruka Therapeutics by 5.8% in the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock worth $62,382,000 after acquiring an additional 112,499 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: BTIG reiterated a “buy” rating and raised its price target to $73 (≈84.6% upside vs. $39.54), signaling strong commercial comparables for ORKA‑001 that support a materially higher valuation. BTIG reiterates buy on Oruka
• Positive Sentiment: Stifel Nicolaus raised its price target to $72 and kept a “buy” call (≈82% upside), adding another institutional endorsement that likely amplified buying interest. Stifel raises PT to $72
• Positive Sentiment: Guggenheim reaffirmed a “buy” and a $60 target (~52% upside), while Wedbush maintained an “outperform” with a $45 target (~14% upside) — multiple firms pointing to upside helps validate the story for momentum traders and long-only investors. Guggenheim & Wedbush notes
• Positive Sentiment: Oruka reported Q4 results: EPS of ($0.45) beat consensus of ($0.61), showing better-than-expected financial performance and relieving some near-term execution risk. Quarterly results and press release
• Positive Sentiment: Corporate update: ORKA‑001 EVERLAST‑A 16‑week data are now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — faster enrollment reduces timeline risk and makes near-term clinical catalysts clearer. Corporate update / GlobeNewswire

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.